Aug. 31 at 7:11 AM
$ELDN I understand why many
$ELDN holders are nervous about the silence after the 12/12 insulin-independence result. I am one of them.
But there are a few positive signs quietly developing in the background.
HHS is actively reviewing donor-islet reclassification.
If that happens, islet transplantation could become much more accessible in the U.S.
That could greatly increase the relevance of tegoprubart’s 12/12 result and strengthen Eledon’s T1D opportunity.
And there are two more things I keep watching:
- Gros is heavily rewarded if Eledon reaches
$600M–
$1.5B in value.
- And Eledon already has a history with strong biotech investors like BVF and others.
So the silence may simply mean they are trying to get the right financing, at the right valuation, with the right investors.
No proof of a hidden deal. But these are encouraging signs.
